UnitedHealth: Solid Earnings and Raised Guidance Offset by Cost Pressures, Supporting a Hold Rating

Analyst Ryan Langston from TD Cowen maintained a Hold rating on UnitedHealth and increased the price target to $337.00 from $311.00.

Ryan Langston has given his Hold rating due to a combination of factors, including UnitedHealth’s solid first‑quarter performance and improved earnings outlook, balanced against remaining uncertainties. The company delivered a meaningful earnings beat and raised its 2026 and 2027 EPS guidance, prompting upward revisions to estimates and a higher price target based on a 2027 valuation multiple.

At the same time, Langston notes that medical cost trends, Medicare Advantage margin normalization, and ongoing pressure in the Medicaid business temper the upside. While Optum Health is progressing well and management is investing heavily in AI with benefits expected later in 2026 and 2027, much of the anticipated margin and growth improvement remains ahead, leading to a more neutral stance at current valuation levels.

In another report released yesterday, Deutsche Bank also assigned a Hold rating to the stock with a $360.00 price target.